In the midst of the Novo Nordisk vs. Eli Lilly advertising dispute, it's clear that the pharmaceutical industry's cutthroat competition has reached new lows. This case highlights the urgent need for stricter regulations on drug marketing to prevent misleading claims and protect consumers. Let's not sugarcoat it: deceptive advertising in healthcare is a threat to public health, and it's time for the FDA to step in and put a stop to it.